Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus endocrine adjuvant therapy in middle/high-risk HR-positive early breast cancer
ChiCTR2500107587Phase 4Recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dalpiciclib in breast cancer (2 arms), sponsored by Jilin Provincial Cancer Hospital. Primary endpoint: Invasive disease-free survival. Started Aug 2025; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500107587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107587.